Lesson plan

IBI311

IBI311 is a monoclonal antibody that targets IGF-1R and is being developed for thyroid eye disease. It is in a Phase III clinical trial as of 2023.

Back to article

Article summary

IBI311 is a monoclonal antibody that targets IGF-1R and is being developed for thyroid eye disease. It is in a Phase III clinical trial as of 2023.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.